• SELLAS Life Sciences Group has reached the pre specified 80th event in its Phase 3 REGAL trial, triggering final analysis and paving the way for multiple AML data readouts, including topline Phase 2 results for SLS009 in both newly diagnosed and previously treated patients.
• The cluster of late stage and mid stage AML readouts concentrates clinical risk for SELLAS Life Sciences Group into a short window, which may influence how the business secures future funding, structures partnerships and prioritizes its cancer vaccine and CDK9 inhibitor programs.
• We will now look at how SELLAS Life Sciences Group’s imminent REGAL survival data could reshape the broader investment narrative around the stock.

Scan how SELLAS Life Sciences Group fits…